Literature DB >> 23833565

NKG2D ligands as therapeutic targets.

Paul Spear1, Ming-Ru Wu, Marie-Louise Sentman, Charles L Sentman.   

Abstract

The Natural Killer Group 2D (NKG2D) receptor plays an important role in protecting the host from infections and cancer. By recognizing ligands induced on infected or tumor cells, NKG2D modulates lymphocyte activation and promotes immunity to eliminate ligand-expressing cells. Because these ligands are not widely expressed on healthy adult tissue, NKG2D ligands may present a useful target for immunotherapeutic approaches in cancer. Novel therapies targeting NKG2D ligands for the treatment of cancer have shown preclinical success and are poised to enter into clinical trials. In this review, the NKG2D receptor and its ligands are discussed in the context of cancer, infection, and autoimmunity. In addition, therapies targeting NKG2D ligands in cancer are also reviewed.

Entities:  

Keywords:  CD8+ T cells; MICA; NK cells; Rae-1; immunotherapy

Mesh：

Substances：

Year:  2013        PMID： 23833565      PMCID： PMC3700746     

Source DB:  PubMed          Journal:  Cancer Immun        ISSN： 1424-9634


  172 in total

1.  NKG2D receptor regulates human effector T-cell cytokine production.

Authors:  Amorette Barber; Charles L Sentman
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

2.  Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.

Authors:  Masahisa Jinushi; F Stephen Hodi; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

3.  A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo.

Authors:  Elke Pogge von Strandmann; Hinrich P Hansen; Katrin S Reiners; Roland Schnell; Peter Borchmann; Sabine Merkert; Venkateswara R Simhadri; Andreas Draube; Marcel Reiser; Ingvill Purr; Michael Hallek; Andreas Engert
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

4.  TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.

Authors:  Courtney A Crane; Seunggu J Han; Jeffery J Barry; Brian J Ahn; Lewis L Lanier; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2009-11-05       Impact factor: 12.300

5.  NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection.

Authors:  Monia Draghi; Achal Pashine; Bharati Sanjanwala; Ketevan Gendzekhadze; Claudia Cantoni; David Cosman; Alessandro Moretta; Nicholas M Valiante; Peter Parham
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

6.  BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.

Authors:  Nicolas Boissel; Delphine Rea; Vannary Tieng; Nicolas Dulphy; Manuel Brun; Jean-Michel Cayuela; Philippe Rousselot; Ryad Tamouza; Philippe Le Bouteiller; François-Xavier Mahon; Alexander Steinle; Dominique Charron; Hervé Dombret; Antoine Toubert
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

7.  Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.

Authors:  Hequan Li; Yanmei Han; Qiuli Guo; Minggang Zhang; Xuetao Cao
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

8.  NKG2D blockade prevents autoimmune diabetes in NOD mice.

Authors:  Kouetsu Ogasawara; Jessica A Hamerman; Lauren R Ehrlich; Helene Bour-Jordan; Pere Santamaria; Jeffrey A Bluestone; Lewis L Lanier
Journal:  Immunity       Date:  2004-06       Impact factor: 31.745

9.  Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.

Authors:  Maria Grazia Ruocco; Karsten A Pilones; Noriko Kawashima; Michael Cammer; Julie Huang; James S Babb; Mengling Liu; Silvia C Formenti; Michael L Dustin; Sandra Demaria
Journal:  J Clin Invest       Date:  2012-09-04       Impact factor: 14.808

10.  Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells.

Authors:  Norman Nausch; Ioanna E Galani; Eva Schlecker; Adelheid Cerwenka
Journal:  Blood       Date:  2008-08-27       Impact factor: 22.113
View more
  109 in total

1.  Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.

Authors:  Lin Xiao; Dongzhi Cen; Haining Gan; Yan Sun; Nanqi Huang; Hanzhen Xiong; Qiongmei Jin; Liqun Su; Xuejuan Liu; Kejian Wang; Guangrong Yan; Tianfa Dong; Shangbiao Wu; Pengzhi Zhou; Jinshan Zhang; Weixiang Liang; Junlan Ren; Yaoshu Teng; Can Chen; Xue Hu Xu
Journal:  Mol Ther       Date:  2019-03-20       Impact factor: 11.454

Review 2.  Chimeric antigen receptor T cell therapies for acute myeloid leukemia.

Authors:  Bin Gu; Jianhong Chu; Depei Wu
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

3.  Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.

Authors:  Susanne H Baumeister; Joana Murad; Lillian Werner; Heather Daley; Helene Trebeden-Negre; Joanina K Gicobi; Adam Schmucker; Jake Reder; Charles L Sentman; David E Gilham; Frédéric F Lehmann; Ilene Galinsky; Heidi DiPietro; Kristen Cummings; Nikhil C Munshi; Richard M Stone; Donna S Neuberg; Robert Soiffer; Glenn Dranoff; Jerome Ritz; Sarah Nikiforow
Journal:  Cancer Immunol Res       Date:  2018-11-05       Impact factor: 11.151

4.  p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells.

Authors:  Alessandra Soriani; Cristiana Borrelli; Biancamaria Ricci; Rosa Molfetta; Alessandra Zingoni; Cinzia Fionda; Silvia Carnevale; Maria Pia Abruzzese; Maria Teresa Petrucci; Maria Rosaria Ricciardi; Giuseppe La Regina; Erica Di Cesare; Patrizia Lavia; Romano Silvestri; Rossella Paolini; Marco Cippitelli; Angela Santoni
Journal:  Oncoimmunology       Date:  2016-12-02       Impact factor: 8.110

5.  Intratumoral natural killer cells show reduced effector and cytolytic properties and control the differentiation of effector Th1 cells.

Authors:  Sourav Paul; Neeraja Kulkarni; Girdhari Lal
Journal:  Oncoimmunology       Date:  2016-09-20       Impact factor: 8.110

Review 6.  NKG2D Receptor and Its Ligands in Host Defense.

Authors:  Lewis L Lanier
Journal:  Cancer Immunol Res       Date:  2015-06       Impact factor: 11.151

7.  NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors.

Authors:  Claire Godbersen; Tiffany A Coupet; Amelia M Huehls; Tong Zhang; Michael B Battles; Jan L Fisher; Marc S Ernstoff; Charles L Sentman
Journal:  Mol Cancer Ther       Date:  2017-05-12       Impact factor: 6.261

8.  Toxicity Induced by a Bispecific T Cell-Redirecting Protein Is Mediated by Both T Cells and Myeloid Cells in Immunocompetent Mice.

Authors:  Claire Godbersen-Palmer; Tiffany A Coupet; Zakaria Grada; Samuel C Zhang; Charles L Sentman
Journal:  J Immunol       Date:  2020-04-15       Impact factor: 5.422

9.  Hemacytotoxicity and natural killer lytic index: New parameters to evaluate natural killer cell immunity for clinical use in cancer.

Authors:  Hyung Gun Maeng; Su Jin Lee; Yun A Lee; Hye Jeong Lee; Young Joo Kim; Jong Kyun Lee; Jae Cheol Kim; Joungbum Choi
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

10.  In vivo Anti-Cancer Effects of Resveratrol Mediated by NK Cell Activation.

Authors:  Yoojin Lee; Heewook Shin; Jongsun Kim
Journal:  J Innate Immun       Date:  2020-09-16       Impact factor: 7.349
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.